6414
S. Duan, K. D. Moeller / Tetrahedron 57 )2001) 6407±6415
132.5, 131.8, 128.7, 128.6, 128.0, 127.1, 126.1, 80.1, 79.9,
66.8, 66.1, 60.8, 52.0, 51.9, 47.9, 47.2, 41.0, 40.5, 28.2,
17.6, 17.4; IR 5neat/NaCl) 3033, 2971, 2935, 1749, 1710,
1690, 1452, 1392, 1364, 1253, 1199, 1173, 959, 757,
698 cm21; LRMS 5FAB) 346 5MH1, 6), 246 520), 204
517), 185 554), 137 5500), 93 5100); HRMS C20H28NO4
5MH1) calcd 346.2018, found 346.2013.
552); HRMS C20H28NO4 5MH1) calcd 346.2018, found
346.2017.
1.1.14. +3S,6R,8R,9R)-1,4-Diaza-3-benzyl-9-carbomethoxy-
8-phenyl-2-oxo bicyclo-[4, 3, 0] nonane +15). Starting from
5b-ent, the bicyclic analog 15 was prepared in a fashion
identical to that described for the preparation of 14 from
1
5b. TLC 5Et2O/CH3OH 59:1)) Rf0.30; H NMR 5CDCl3/
600 MHz) d 1.78 5bs, 1H), 2.02 5dt, 1H, J10.8, 15.6 Hz),
2.29±2.34 5m, 1H), 2.56 5dd, 1H, J12.6, 14.4 Hz), 3.04
5dd, 1H, J10.2, 16.8 Hz), 3.24 5s, 3H), 3.28 5dd, 1H,
J10.8, 15.6 Hz), 3.39 5dd, 1H, J4.8, 16.8 Hz), 3.68
5dd, 1H, J11.4, 3.6 Hz), 3.77 5dt, 1H, J4.8, 10.8 Hz),
4.19±4.25 5m, 1H), 5.16 5d, 1H, J10.8 Hz) 7.17±7.36
5m, 10H); 13C NMR 5CDCl3/150 MHz) d 169.6, 168.9,
139.2, 137.8, 129.3, 128.5, 128.2, 128.0, 127.2, 126.6,
63.8, 59.6, 59.2, 51.4, 48.8, 44.2, 38.5, 36.2; IR 5neat/
NaCl) 3486, 3222, 3027, 2945, 1743, 1647, 1496, 1452,
1431, 1370, 1202, 1178, 754, 699 cm21; LRMS 5FAB)
371 5M1Li, 100), 337 510), 280 530), 218 512), 134 510),
91 516); HRMS C22H24N2O3Li 5M1Li) calcd 371.1947,
found 371.1937.
1.1.11. +3R,5R)-N-tert-Butyloxycarbonyl-3-phenyl-5-+trans-
1-propenyl)-d-proline methyl ester +5a-ent). Starting
from
52R,3R)-2-N-5tert-butyloxycarbonyl)
amino]-3-
phenyl-4-pentenoic acidaa the enantiomer of 5a 55a-ent)
was synthesized in a fashion identical to that described
above for 5. TLC 5Et2O/hexane 51:1)) Rf0.40;
20
[a]D 114.68 5c 0.205, ether); 1H NMR 5CDCl3/
300 MHz) d 1.38 5s, 5.4H), 1.44 5s, 3.6H), 1.71±1.74 5m,
3H), 1.83±1.90 5m, 1H), 2.70±2.86 5m, 1H), 3.22 5s, 1.2H),
3.26 5s, 1.8H), 3.71±3.84 5m, 1H), 4.49±4.74 5m, 2H),
5.50±5.70 5m, 2H), 7.12±7.33 5m, 5H); 13C NMR 5CDCl3/
75 MHz) d 171.6, 171.5, 153.3, 136.5, 136.4, 131.1, 128.3,
127.9, 127.8, 127.4, 125.5, 80.0, 79.9, 64.9, 64.2, 58.3, 51.1,
45.2, 44.3, 34.2, 33.3, 28.3, 28.2, 17.7, 17.5; IR 5neat/NaCl)
3033, 2981, 2950, 1749, 1708, 1695, 1390, 1367, 1176,
1132, 786, 698 cm21; LRMS 5FAB) 346 5MH1, 6), 344
58), 290 558), 246 5100), 230 557), 204 526), 186 556), 93
534); HRMS C20H28NO4 5MH1) calcd 346.2018, found
346.2023.
Acknowledgements
We thank the National Institutes ofHealth 5GM5324001)
for their generous ®nancial support. In addition, we thank
the Washington University High Resolution NMR
Facility, partially supported by NIH grants RR02004,
RR05018, and RR07155, and the Washington University
Mass Spectrometry Resource Center, partially supported
by NIH RR00954, for their assistance.
1.1.12. +3R,5R)-N-tert-Butyloxycarbonyl-3-phenyl-5-+trans-
1-propenyl)-l-proline methyl ester +6-ent). The enantio-
mer of 6 56-ent) was synthesized in a fashion identical to
that used to prepare 6. TLC 5Et2O/hexane 51:1)) Rf0.45;
[a]D 225.08 5c 0.16, ether); 1H NMR 5CDCl3/600 MHz)
20
d 1.42 5s, 5.4H), 1.44 5s, 3.6H), 1.75 5d, 3H, J6.6 Hz), 2.08
5m, 1H), 2.28 5m, 1H), 3.48±3.52 5m, 1H), 3.67 5s, 1.8H),
3.69 5s, 1.2H), 4.22±4.57 5m, 2H), 5.62±5.90 5m, 2H),
7.23±7.35 5m, 5H); 13C NMR 5CDCl3/150 MHz) d 173.2,
154.2, 153.3, 140.1, 139.3, 131.3, 130.8, 128.7, 128.7,
128.5, 128.3, 128.2, 127.8, 127.3, 127.1, 126.4, 80.2, 80.0,
66.6, 65.8, 59.7, 59.2, 52.1, 51.8, 47.9, 47.0, 40.2, 39.6,
29.6, 28.2, 17.8, 17.6; IR 5neat/NaCl) 3033, 2971, 2935,
1752, 1702, 1695, 1454, 1392, 1364, 1250, 1196, 1168,
1121, 964, 760, 698 cm21; LRMS 5FAB) 346 5MH1, 10),
290 535), 246 5100), 230 544), 204 532), 186 540), 157 520),
117 520), 91 530); HRMS C20H28NO4 5MH1) calcd
346.2018, found 346.2021.
Appendix A. Supplementary material available
The proton and carbon spectra are included for all new
compounds along with 2D-NOESY data for compounds
5a, 6, 7, 14, and 15 542 pages).
References
1. For a recent review concerning the use oflactam based pepti-
domimetics see: 5a) Hanessian, S.; McNaughton-Smith, G.;
Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 53, 12789.
For more recent references see: 5b) Polyak, F.; Lubell, W. D.
J. Org. Chem. 1998, 63, 5937. 5c) Curran, T. P.; Marcaurell,
L. A.; O'Sullivan, K. M. Org. Lett. 1999, 1, 1998. 5d) Gosselin,
F.; Lubell, W. D. J. Org. Chem. 2000, 65, 2163 as well as
references therein.
1.1.13. +3R,5S)-N-tert-Butyloxycarbonyl-3-phenyl-5-+trans-
1-propenyl)-l-proline methyl ester +7-ent). The enantio-
mer of 7 57-ent) was prepared in a fashion identical to that
described for the preparation of 7. TLC 5Et2O/hexane 51:1))
Rf0.36; [a]D 115.98 5c 0.315, ether); 1H NMR 5CDCl3/
20
2. 5a) Beal, L. M.; Liu, B.; Chu, W.; Moeller, K. D. Tetrahedron
2000, 56, 10113. 5b) Beal, L. M.; Moeller, K. D. Tetrahedron
Lett. 1998, 39, 4639. For a complementary N-acyliminium ion
cyclization route to analogs like I see: 5c) Li, W.; Hanau, C. E.;
d'Avignon, A.; Moeller, K. D. J. Org. Chem. 1995, 60, 8155.
5d) Li, W.; Moeller, K. D. J. Am. Chem. Soc. 1996, 118, 10106.
5e) Chu, W.; Moeller, K. D. Tetrahedron Lett. 1999, 40, 7939.
3. 5a) Tong, Y.; Fobian, Y. M.; Wu, M.; Boyd, N. D.; Moeller,
K. D. J. J. Org. Chem. 2000, 65, 2484. 5b) Fobian, Y. M.;
Moeller, K. D. In Methods in Molecular Medicine: Peptidomi-
metic Protocols, Kazmierski, W. M., Ed.; Humana: Totawa,
1999; pp 259.
600 MHz) d 1.40 5s, 4.5H), 1.42 5s, 4.5H), 1.65±1.67
5m, 3H), 1.90±1.95 5m, 1H), 2.44±2.51 5m, 1H), 3.35±
3.39 5m, 1H), 3.69 5s, 3H), 4.35±4.50 5m, 2H), 5.27±5.65
5m, 2H), 7.25±7.33 5m, 5H); 13C NMR 5CDCl3/600 MHz)
d 173.3, 172.8, 154.5, 153.3, 140.3, 140.0, 132.6, 131.9,
128.6, 127.1, 126.2, 126.1, 80.1, 79.9, 66.9, 66.2, 60.8,
52.1, 51.9, 48.0, 47.2, 41.1, 40.5, 28.2, 17.7, 17.4; IR
5neat/NaCl) 3033, 2971, 2935, 1749, 1710, 1692, 1452,
1395, 1367, 1253, 1199, 1168, 959, 757, 698 cm21
;
LRMS 5FAB) 346 5MH1, 6), 344 58), 290 548), 246
5100), 204 520), 186 547), 1579 516), 117 518), 93